Publicaciones en colaboración con investigadores/as de Queen Mary University of London (21)

2026

  1. Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction

    The New England journal of medicine, Vol. 394, Núm. 10, pp. 958-968

  2. Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024

    Journal of the European Academy of Dermatology and Venereology, Vol. 40, Núm. 2, pp. 210-223

  3. Switch to single-tablet bictegravir–lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial

    The Lancet, Vol. 407, Núm. 10535, pp. 1249-1258

2025

  1. Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis

    Journal of the American College of Cardiology, Vol. 85, Núm. 7, pp. 685-695

  2. Left ventricular ejection fraction decline and cardiovascular events in suspected cardiomyopathy with excessive trabeculation: toward precision medicine

    Revista Espanola de Cardiologia, Vol. 78, Núm. 11, pp. 934-944

  3. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement

    JAMA dermatology, Vol. 161, Núm. 1, pp. 87-95

  4. Treatment and outcomes of chronic coronary syndromes: the EORP EURECA imaging registry

    European Heart Journal, Vol. 46, Núm. 39, pp. 3922-3927

2024

  1. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

    The Lancet HIV, Vol. 11, Núm. 2, pp. e75-e85

  2. Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

    AIDS (London, England), Vol. 38, Núm. 7, pp. 983-991

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  3. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  4. Use of cardiac imaging in chronic coronary syndromes: the EURECA Imaging registry

    European Heart Journal, Vol. 44, Núm. 2, pp. 142-158

2021

  1. Fecal microbiota transplantation in HIV: A pilot placebo-controlled study

    Nature Communications, Vol. 12, Núm. 1

  2. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  3. The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

    European Heart Journal, Vol. 42, Núm. 13, pp. 1254-1269

2020

  1. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

    European Heart Journal, Vol. 41, Núm. 1, pp. 111-188

  2. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)

    European Journal of Heart Failure, Vol. 22, Núm. 9, pp. 1504-1524

  3. Understanding clinical decision-making during the COVID-19 pandemic: A cross-sectional worldwide survey

    EClinicalMedicine, Vol. 27

2018

  1. Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 11, pp. 2927-2935